Product Center
Approved as Taizhou Engineering Research Center
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-07-03
- Views:
(Summary description)Recently, the Taizhou Municipal Development and Reform Commission announced the list of 2024 Taizhou Engineering Research Centers, and the "Taizhou Engineering Research Center for Human Vaccine Technology Innovation" established by Ab&B Bio-Tech Co. (hereinafter referred to as "Ab&B Bio") was successfully recognized as a Municipal Engineering Research Center.
Approved as Taizhou Engineering Research Center
(Summary description)Recently, the Taizhou Municipal Development and Reform Commission announced the list of 2024 Taizhou Engineering Research Centers, and the "Taizhou Engineering Research Center for Human Vaccine Technology Innovation" established by Ab&B Bio-Tech Co. (hereinafter referred to as "Ab&B Bio") was successfully recognized as a Municipal Engineering Research Center.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-07-03 17:05
- Views:
Recently, the Taizhou Municipal Development and Reform Commission announced the list of 2024 Taizhou Engineering Research Centers, and the "Taizhou Engineering Research Center for Human Vaccine Technology Innovation" established by Ab&B Bio-Tech Co. (hereinafter referred to as "Ab&B Bio") was successfully recognized as a Municipal Engineering Research Center.
It is understood that this recognition of the Taizhou Engineering Research Center aims to deeply practice the new development concept and innovation-driven development strategy, focusing on the development of new quality productivity in accordance with local conditions, accelerate the deep integration of the innovation chain, industrial chain, capital chain and talent chain, and promote the high-quality development of the city's strategic emerging industries.
Ab&B Bio will, through the continuous construction of the Taizhou Human Vaccine Technology Innovation Engineering Research Center, aim at solving the huge unmet demand for innovative human vaccines, combine this effort with the actual situation of the enterprise, further enhance the innovation level of the company's technology platform, continue to strengthen talent development and team building, carry out scientific and technological innovation and key core technology research, develop new-quality productive forces, and continuously promote the generation of original scientific and technological achievements. The company will continue to strengthen talent training and team building, carry out scientific and technological innovation and key core technology research, develop new productivity, continuously promote the output of original scientific and technological achievements, and contribute to the high-quality development of the biomedical industry and the protection of people's lives, health and social welfare.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
